The global angina pectoris drugs market size was valued at USD 12.9 billion in 2025 and is projected to grow from USD 13.4 billion in 2026 to USD 17.6 billion by 2033, at a CAGR of 4.0% from 2026 to 2033. The North America dominated the global market, accounting for the largest revenue share of 40.0% in 2025. Advancements in personalized cardiovascular medicine and novel drug delivery systems are driving market expansion.
Moreover, worldwide market growth is fueled by the escalating prevalence of cardiac disorders, including coronary heart disease. Pharmaceutical companies are investing heavily in clinical trials to develop innovative treatments with improved efficacy, further propelling market growth. These developments are expected to significantly contribute to the market’s continued expansion.
The global angina pectoris drugs market is driven by a combination of factors, including the increasing occurrence of cardiovascular diseases worldwide. The growing demand for effective treatments is driven by the fact that cardiovascular diseases are a leading contributor to global mortality rates. Advances in drug delivery systems, such as transdermal patches and sustained-release formulations, are also boosting the efficiency and patient compliance of angina pectoris medications.
The growing geriatric population is another key driver of the market, as the elderly are more susceptible to cardiovascular diseases. This demographic shift presents an opportunity for pharmaceutical companies to develop targeted therapies that address the unique needs of older adults and improve their quality of life. Strategic partnerships and collaborations between pharmaceutical companies and research institutions are also driving market growth by advancing the development of innovative drug formulations and accelerating drug discovery.
Advancements in cardiology treatment, ongoing research and development efforts, and a growing number of drug approvals from regulatory bodies such as the FDA are also driving market growth. The rise in retail pharmacies and patient preference for purchasing angina drugs through these channels is creating market opportunities. As the global population continues to age, there will be increasing demand for effective treatments for angina pectoris, presenting an opportunity for pharmaceutical companies to develop and market new products to meet this growing need.
▪ Canada
▪ Mexico
▪ Germany
▪ France
▪ Italy
▪ Spain
▪ Denmark
▪ Sweden
▪ Norway
▪ China
▪ India
▪ Australia
▪ South Korea
▪ Thailand
▪ Argentina
▪ Saudi Arabia
▪ UAE
▪ Kuwait
This product will be delivered within 1-3 business days.
Moreover, worldwide market growth is fueled by the escalating prevalence of cardiac disorders, including coronary heart disease. Pharmaceutical companies are investing heavily in clinical trials to develop innovative treatments with improved efficacy, further propelling market growth. These developments are expected to significantly contribute to the market’s continued expansion.
The global angina pectoris drugs market is driven by a combination of factors, including the increasing occurrence of cardiovascular diseases worldwide. The growing demand for effective treatments is driven by the fact that cardiovascular diseases are a leading contributor to global mortality rates. Advances in drug delivery systems, such as transdermal patches and sustained-release formulations, are also boosting the efficiency and patient compliance of angina pectoris medications.
The growing geriatric population is another key driver of the market, as the elderly are more susceptible to cardiovascular diseases. This demographic shift presents an opportunity for pharmaceutical companies to develop targeted therapies that address the unique needs of older adults and improve their quality of life. Strategic partnerships and collaborations between pharmaceutical companies and research institutions are also driving market growth by advancing the development of innovative drug formulations and accelerating drug discovery.
Advancements in cardiology treatment, ongoing research and development efforts, and a growing number of drug approvals from regulatory bodies such as the FDA are also driving market growth. The rise in retail pharmacies and patient preference for purchasing angina drugs through these channels is creating market opportunities. As the global population continues to age, there will be increasing demand for effective treatments for angina pectoris, presenting an opportunity for pharmaceutical companies to develop and market new products to meet this growing need.
Global Angina Pectoris Drugs Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global angina pectoris drugs market report by type, drug class, distribution channel, and region:Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Stable Angina
- Unstable Angina
- Microvascular Angina
- Prinzmetal Angina
Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
- Beta Blockers
- Calcium Antagonists
- Nitrates
- Anticoagulants
- Anti-Platelets
- Other Drug Classes
Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
▪ Canada
▪ Mexico
- Europe
▪ Germany
▪ France
▪ Italy
▪ Spain
▪ Denmark
▪ Sweden
▪ Norway
- Asia Pacific
▪ China
▪ India
▪ Australia
▪ South Korea
▪ Thailand
- Latin America
▪ Argentina
- Middle East & Africa
▪ Saudi Arabia
▪ UAE
▪ Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Angina Pectoris Drugs Market Variables, Trends, & Scope
Chapter 4. Angina Pectoris Drugs Market: Type Estimates & Trend Analysis
Chapter 5. Angina Pectoris Drugs Market: Drug Class Estimates & Trend Analysis
Chapter 6. Angina Pectoris Drugs Market: Distribution Channel Estimates & Trend Analysis
Chapter 7. Angina Pectoris Drugs Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
- Pfizer Inc.
- Bayer AG
- AstraZeneca
- Gilead Sciences, Inc.
- Novartis AG
- GSK plc.
- Merck & Co., Inc.
- Amgen Inc.
- Lilly USA, LLC
- Otsuka Pharmaceutical Co., Ltd.
- Sanofi S.A.
- Boehringer Ingelheim International GmbH
